A bioprinted implant made with living human cells reaches the eye

A living, laboratory-made corneal implant has crossed the boundary from a manufacturing experiment into human surgery. Rambam Health Care Campus in Israel reported in November 2025 that it had implanted the tissue in late October in an eye that met the definition of legal blindness. This is a look back at that clinical milestone, not a claim that the operation happened today.

The cornea is the transparent front surface through which light enters the eye. Conventional transplantation replaces damaged tissue with donated corneal tissue. As Johns Hopkins Medicine explains, the replacement may involve the full thickness or selected layers, depending on the disease. Follow-up remains necessary, and complications such as infection and rejection remain possible. Manufacturing tissue does not make those clinical responsibilities disappear.

In an August 2026 interview, Precise Bio's founders described printing human corneal endothelial cells onto collagen material. These are cells associated with the back layer of the cornea, not a replacement retina, optic nerve or whole eyeball. The proposed advantage is to expand cells from donated material into a supply of implants, rather than treating the original tissue as the only usable unit. That proposition still begins with a donor.

There is substantial earlier work to compare it with. A Nature Biotechnology paper published in 2022 described a cell-free implant made from porcine collagen, tested in 20 people with advanced keratoconus and followed for two years. Keratoconus involves thinning and distortion of the cornea. That approach reshaped existing tissue; living cultured human cells represent a different route and disease target. It would therefore be wrong to describe this as the first occasion on which any engineered corneal material reached a person.

Rambam identified its work as a Phase 1 study focused on safety and tolerability. Implanting tissue successfully is not the same as establishing lasting benefit across a patient population. For prospective recipients, the decisive questions will be dependable production, durable vision, complications and access. The meaningful advance is entry into human testing, with those questions still open.

Original event: late October 2025. Hospital announcement: November 20, 2025.